NRC NRC HEALTH
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 70487 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY3.4%
TTM net income YoY-60.6%
TTM EPS YoY6,909.9%
Revenue 3-yr CAGR-1.1%
Net income 3-yr CAGR-39.3%
Margins
Gross margin—
Operating margin11.1%
Net margin4.5%
FCF margin12.8%
EBITDA margin17.0%
Returns
ROE248.1%
ROA4.7%
ROIC (approx.)10.9%
Asset turnover1.05x
Leverage & solvency
Liabilities / assets106.6%
Debt / equity—
Current ratio0.64x
Interest coverage2.91x
Cash quality & payout
Operating cash flow / net income3.69x
Accruals ratio-12.6%
Payout ratio209.2%
Capex / revenue3.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $137.39M | $143.06M | $148.58M | $151.57M | $147.95M |
| SG&A expense | $54.80M | $44.91M | $46.62M | $42.70M | $38.96M |
| Operating income | $22.59M | $35.19M | $40.05M | $46.54M | $50.27M |
| Interest expense | $4.76M | $2.60M | $862,000 | $1.21M | $1.67M |
| Pretax income | $17.84M | $32.69M | $39.96M | $42.81M | $48.62M |
| Income tax | $6.25M | $7.91M | $8.99M | $11.02M | $11.15M |
| Net income | $11.60M | $24.78M | $30.97M | $31.80M | $37.47M |
| EBITDA | $30.21M | $41.22M | $45.94M | — | — |
| EPS (basic) | 50.00 | 1.05 | 1.26 | 1.28 | 1.47 |
| EPS (diluted) | 50.00 | 1.04 | 1.25 | 1.27 | 1.46 |
| Dividends declared per share | 0.52 | 0.48 | 1.48 | 0.84 | 0.48 |
| Weighted avg. shares (diluted) | 22.40M | 23.74M | 24.67M | 25.05M | 25.64M |
| Balance sheet | |||||
| Cash & equivalents | $4.14M | $4.23M | $6.65M | $25.03M | $54.36M |
| Receivables | $11.11M | $11.05M | $12.38M | $14.46M | $13.73M |
| Current assets | $20.21M | $19.60M | $24.36M | $43.72M | $73.71M |
| PP&E, net | $40.47M | $38.27M | $28.20M | $17.25M | $12.39M |
| Goodwill | $66.15M | $66.15M | $61.61M | $61.61M | $61.61M |
| Intangibles | $2.23M | $2.62M | $1.47M | $1.61M | $1.79M |
| Total assets | $134.88M | $132.54M | $122.44M | $130.46M | $157.54M |
| Current liabilities | $36.62M | $35.86M | $36.20M | $33.42M | $40.39M |
| Short-term debt | $4.01M | — | — | — | — |
| Long-term debt | $75.02M | $57.90M | $29.47M | $22.32M | $26.62M |
| Total debt | $79.03M | $57.90M | $29.47M | $22.32M | $26.62M |
| Total liabilities | $120.89M | $101.25M | $73.48M | $58.43M | $72.20M |
| Shareholders' equity | $13.99M | $31.28M | $48.95M | $72.03M | $85.34M |
| Net debt | $74.90M | $53.66M | $22.82M | -$2.71M | -$27.74M |
| Shares outstanding | 22.64M | 23.08M | 24.22M | 24.63M | 25.36M |
| Cash flow statement | |||||
| Operating cash flow | $26.45M | $34.62M | $38.11M | $36.27M | $46.34M |
| Capital expenditure | $10.71M | $15.45M | $15.78M | $9.84M | $5.51M |
| Free cash flow | $15.74M | $19.18M | $22.33M | $26.43M | $40.83M |
| Investing cash flow | -$10.71M | -$20.28M | -$15.78M | -$9.84M | -$8.51M |
| Financing cash flow | -$15.84M | -$16.76M | -$40.71M | -$55.58M | -$18.16M |
| Depreciation & amortization | $7.62M | $6.02M | $5.90M | — | — |
| Stock-based compensation | $3.31M | $284,000 | $935,000 | $1.20M | $623,000 |
| Dividends paid | $10.98M | $11.45M | $36.37M | $20.96M | $9.16M |
| Share buybacks | $20.18M | $30.95M | $19.10M | $27.62M | $4.14M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.